IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Acquired by Fiera Capital Corp

Fiera Capital Corp raised its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 2.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,209,865 shares of the company's stock after acquiring an additional 25,398 shares during the quarter. Fiera Capital Corp owned approximately 1.38% of IDEAYA Biosciences worth $19,818,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Mariner LLC increased its stake in IDEAYA Biosciences by 9.8% during the fourth quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after acquiring an additional 869 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of IDEAYA Biosciences by 6.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,301 shares of the company's stock valued at $349,000 after buying an additional 1,214 shares in the last quarter. NEOS Investment Management LLC grew its stake in shares of IDEAYA Biosciences by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 16,066 shares of the company's stock valued at $413,000 after buying an additional 1,577 shares in the last quarter. CWM LLC grew its stake in shares of IDEAYA Biosciences by 325.7% in the first quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after buying an additional 1,814 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of IDEAYA Biosciences in the fourth quarter valued at $47,000. Institutional investors and hedge funds own 98.29% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on IDYA. The Goldman Sachs Group upgraded IDEAYA Biosciences to a "hold" rating and set a $25.00 target price for the company in a report on Thursday, July 10th. JPMorgan Chase & Co. lifted their target price on IDEAYA Biosciences from $66.00 to $72.00 and gave the company an "overweight" rating in a report on Monday, July 28th. Wells Fargo & Company assumed coverage on IDEAYA Biosciences in a report on Thursday, June 26th. They issued an "overweight" rating and a $44.00 target price for the company. Royal Bank Of Canada raised IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and decreased their price target for the stock from $57.00 to $30.00 in a report on Wednesday, July 9th. Finally, TD Cowen assumed coverage on IDEAYA Biosciences in a report on Tuesday, July 22nd. They set a "buy" rating for the company. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $48.09.

IDEAYA Biosciences Price Performance

NASDAQ IDYA traded down $0.08 during trading hours on Friday, hitting $24.27. The company had a trading volume of 860,814 shares, compared to its average volume of 982,643. The firm's 50 day moving average is $22.07 and its 200 day moving average is $20.35. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of -6.76 and a beta of 0.09. IDEAYA Biosciences, Inc. has a fifty-two week low of $13.45 and a fifty-two week high of $41.08.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period last year, the company earned ($0.53) EPS. On average, equities analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.